

Hydroxycarbamide (hydroxyurea)

Statut de médicament essentiel

Description générale

Hydroxyurea (also known as hydroxycarbamide) is used in the management of sickle cell disease, and in treatment protocols for chronic myeloproliferative disorders.

INN

Hydroxycarbamide

Codes ATC

[L01XX05](#)

Type de médicament

Chemical agent

Historique des statuts LME

Ajouté pour la première fois en 2009 ([TRS 958](#)) pour [Chronic myeloid leukaemia, not elsewhere classified](#)

Ajouté en 2009 ([TRS 958](#)) pour [Squamous cell carcinoma of oropharynx](#)

Ajouté en 2011 ([TRS 965](#)) pour [Other specified sickle cell disorders or other haemoglobinopathies](#)

Retiré en 2015 ([TRS 994](#)) pour [Squamous cell carcinoma of oropharynx](#)

Wikipédia

[Hydroxycarbamide \(hydroxyurea\)](#)

DrugBank

[Hydroxycarbamide \(Hydroxyurea\)](#)

Recommandations

Section

Cytotoxic medicines

- Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g

Indications

[Chronic myeloid leukaemia, not elsewhere classified](#) [Squamous cell carcinoma of oropharynx](#)

Section

Medicines for haemoglobinopathies

- Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg

Indications

[Other specified sickle cell disorders or other haemoglobinopathies](#)